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In all neurosurgical cases associated with
anticoagulation/antiplatelet therapy, peri-
operative antithrombotic management of
patients is complicated due to increased
risks of intra- and/or postoperative bleed-
ing or thromboembolic complications.
The potential risk of thrombosis may
increase when anticoagulation/antiplatelet
therapy is stopped perioperatively. On
the other hand, perioperative hemorrhage
may occur more often when anticoagula-
tion/antiplatelet therapy is continued.
In general, the contraindications
to anticoagulation/antiplatelet therapy
include:
• Traumatic brain injury
• Craniotomy
• Hemorrhagic stroke
• Brain tumor
• Uncontrollable hypertension
• Preexisting coagulopathies and/or
advanced hepatic or renal disease
• Other clinical situations.
In certain circumstances increased risk of
thrombosis in a previously placed vascular
stent (particularly, drug-emitting stents),
deep vein thrombosis with a history of
pulmonary embolism, neuroendovascular
procedures, acute cardiovascular insuf-
ficiency, and a risk of acute throm-
bosis, therapy with anticoagulants and
antiplatelet medications is crucial. In
recent years the number of patients, receiv-
ing chronic anticoagulant and antiplatelet
therapy increases consistently both among
adult and pediatric patients (Gentilomo
et al., 2011; Enomoto et al., 2014).
Venous thromboembolism is a signifi-
cant risk in neurosurgical patients which
is explained by the long operating times
of many procedures, prolonged bed rest,
immobility related to motor deficits (e.g.,
in spinal cord injuries or stroke patients),
as well as release of significant amounts
of brain tissue thromboplastin during
surgery and trauma, diuretic therapy used
to reduce cerebral edema, intravascu-
lar volume losses following subarachnoid
hemorrhage, and cerebral salt wasting, etc.
Even though, prophylactic therapy with
anticoagulants and antiplatelet drugs is
effective in reducing the risk of throm-
boembolism, its use in elective neuro-
surgery remains controversial.
Perioperative antithrombotic therapy is
performed more frequently and inten-
sively during neuroendovascular proce-
dures. Although anticoagulation may not
increase the risk of aneurysm rupture, it
would most likely increase the volume
of hemorrhage when aneurysm rupture
occurs and thus increase treatment-related
morbidity and mortality.
Surgery for parenchymal lesions, such
as brain tumors, when the surgery disrupts
small vessels, is associated with a higher
risk for hemorrhage.
Number of studies found no higher
risk in patients treated with heparin or
oral anticoagulation when the prothom-
bine time/International Normalized Ratio
is monitored closely (Altschuler et al.,
1990; Constantini et al., 2001). Other
studies indicate that the incidence of
postoperative hemorrhage is increased in
patients undergoing brain tumor surgery
and receiving heparin or enoxaparin (So
et al., 1983; Dickinson et al., 1998).
Rouine-Rapp and McDermott (2013) rec-
ommend stopping clopidogrel preopera-
tively and using a bridging therapy with
Eptifibatide during surgery (Rouine-Rapp
and McDermott, 2013). The beneficial
effects of the drug were related to its
beneficial pharmacologic profile: follow-
ing intravenous administration, plasma
concentrations are achieved within 5min,
maximum inhibition of platelets occurs
within 15min, and steady state con-
centrations are attained within 4–6 h.
Platelet aggregation usually returns to nor-
mal within 4 h of discontinuing ther-
apy (Rouine-Rapp andMcDermott, 2013).
However, the safety and efficacy of such
bridging therapy needs to be evaluated in
prospective properly designed studies in
various groups of neurosurgical patients
before it can be recommended for routine
clinical use.
As a conclusion, the number of patients
receiving chronic anticoagulation ther-
apy is consistently increasing, and many
of those patients undergo neurosurgical
procedures. This problem needs further
evaluation to optimize the treatment
approaches to these patients. In patients
receiving anticoagulation/antiplatelet
therapy who are scheduled for intracra-
nial surgery, the benefits of such therapy
should be weighed against the associated
risks.
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